Respiratory drugs specialist Vectura said on Wednesday that it has appointed James Ward-Lilley as chief executive officer and director effective 1 October.He will succeed Dr Chris Blackwell, who as previously announced, leaves the company at the end of this month.Ward-Lilley joins the group from AstraZeneca, where is currently vice president responsible for respiratory, inflammation and autoimmunity strategy.Dr Trevor Phillips will act as interim CEO from the end of June until Ward-Lilley joins.Chairman Bruno Angelici said: "We are delighted that James is joining as CEO. His significant relevant experience in the respiratory market which he has gained within a major global pharmaceutical company will be a considerable asset for Vectura."James joins at an exciting and important time for Vectura and we are confident that the company will continue to grow from strength to strength under his leadership."Vectura shares closed up 0.2% at 180.60p.